Back to top
more

The Joint (JYNT)

(Delayed Data from NSDQ)

$11.08 USD

11.08
34,957

+0.03 (0.27%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $11.07 -0.01 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (159 out of 250)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Joint Corp. (JYNT) Moves 10.1% Higher: Will This Strength Last?

by Zacks Equity Research

The Joint Corp. (JYNT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

The Joint (JYNT) Rises 30% as Q4 Earnings Beat on Higher Clinics

by Zacks Equity Research

The Joint (JYNT) expects 2024 system-wide sales to be within $530-$545 million.

The Joint Corp. (JYNT) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

The Joint Corp. (JYNT) delivered earnings and revenue surprises of 133.33% and 3.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

The Joint (JYNT) to Report Q4 Earnings: Here Are the Key Drivers

by Zacks Equity Research

The Joint's (JYNT) fourth-quarter 2023 results are likely to reflect higher expenses and patient volumes.

Select Medical (SEM) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Select Medical (SEM) delivered earnings and revenue surprises of 16.13% and 3.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Cigna (CI) Nearing a Medicare Advantage Divestment Deal?

by Zacks Equity Research

Cigna's (CI) Medicare Advantage unit's divestment is expected to fetch around $3-$4 billion.

Cigna (CI) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cigna (CI) delivered earnings and revenue surprises of 1.65% and 2.32%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

The Joint (JYNT) Forays Into West Virginia Chiropractic Market

by Zacks Equity Research

The Joint's (JYNT) new facility is positioned near the West Virginia University campus, at a high-traffic shopping center.

The Joint (JYNT) Q2 Earnings Miss Estimates, 2023 View Down

by Zacks Equity Research

The Joint (JYNT) expects to open 100-120 franchised clinics in 2023 compared with 121 opened last year.

The Joint Corp. (JYNT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

The Joint Corp. (JYNT) delivered earnings and revenue surprises of -133.33% and 1.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

The Joint (JYNT) Reaches 900th Clinic Mark With New Texas Unit

by Zacks Equity Research

The Joint (JYNT) moves from the 800th to the 900th clinic milestone in less than a year.

Humana (HUM) Surpasses Q2 Earnings Estimates

by Zacks Equity Research

Humana (HUM) delivered earnings and revenue surprises of 0.68% and 0.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Molina (MOH) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Molina (MOH) delivered earnings and revenue surprises of 11.88% and 0.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Hold Strategy is Apt for The Joint (JYNT) Stock Now

by Zacks Equity Research

The Joint (JYNT) is expected to keep growing due to rising patient visits and new clinic openings.

The Joint (JYNT) Buys Wisconsin Regional Developer Zone Rights

by Zacks Equity Research

The Joint (JYNT) expects the Wisconsin region to hold a total of 53 clinics, of which 21 are currently operating.

The Joint Corp. (JYNT) Surges 10.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

The Joint Corp. (JYNT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

The Joint Corp. (JYNT) delivered earnings and revenue surprises of 850% and 3.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Humana (HUM) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Humana (HUM) delivered earnings and revenue surprises of 1.41% and 1.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

The Joint (JYNT) to Enter Puerto Rico With New Franchise Deal

by Zacks Equity Research

The Puerto Rico deal with the Comerfords marks The Joint's (JYNT) first franchise deal outside the continental United States.

The Joint Corp. (JYNT) Misses Q4 Earnings Estimates

by Zacks Equity Research

The Joint Corp. (JYNT) delivered earnings and revenue surprises of -42.86% and 1.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Molina (MOH) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Molina (MOH) delivered earnings and revenue surprises of 0.99% and 4.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Centene (CNC) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Centene (CNC) delivered earnings and revenue surprises of -1.15% and 0.08%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

The Joint (JYNT) 2022 Visits Grow to 12.2M, Adds New Clinics

by Zacks Equity Research

The Joint's (JYNT) clinic network grows 19% year over year in 2022.

The Joint (JYNT) Expands Operations to Alaska With 3 Clinics

by Zacks Equity Research

The Joint's (JYNT) expansionary move is expected to be a prudent one, given the growing demand for affordable and convenient chiropractic care in the region.

Do Options Traders Know Something About The Joint (JYNT) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to The Joint (JYNT) stock based on the movements in the options market lately.